Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IWEB>Up 28%. 1MM left @ 0.249 then 0.27
IWEB>Up 28%. 1MM left @ 0.249 then 0.27
IWEB>Up 27% on HUGE 100Mil Merger. Thin L2
IWEB>HUge Merger News just out with a private company Currently operating at a $100 million annual revenue run rate, Promark has no debt, over $20,000,000 in current assets and a $10 million line of credit with BB&T bank.
IWEB>Up 27%. Huge Merger news with a company that has 100Mil in Revenue. PPS 0.249. Thin L2.
R/M. See my postings 1-4. Global Arena and 5 of the subsidiaries is mergeging into CSOF. Epecting a share split to reduce the number of shares to around 400K on or before 3/20. Uplisting to a senior exchange such as the nasdaq or amex expected.
URGGGGG! MM's are taking out stop loss and sell orders before we can clear these levels and run. Need more volume.
On barcharts this news just out is a recap from yesterday but has numbers in it;
Gold mine prepped near Prescott, Ariz.
AP - 43 mins ago
Related Stocks
WSRA - Westrn Sierra New
Sym Last Chg Pct
WSRA 0.0125 +0.0025 +25.00%
LAKE HAVASU CITY, Ariz. (AP) — An Arizona mining company says it has started prep work on the Gold Basin gold mine near Prescott.
After studying the mine for the last couple of years, Western Sierra officials say the mine has shown commercial viability and the company says it has filed its technical reports on the mine.
Western Sierra Mining Corp. President Michael Chaffee tells The Associated Press the mine has an estimated half million ounces of gold just waiting to be removed. Chaffee calls it a fairly large deposit.
The mine is located on 330 acres adjacent to the Hassayampa (hah-say-AHM'-puh) River 20 miles south of Prescott and is made up of four claims.
This is going way higher today. MM's are selling at the ASK to get shares. MM's desperate = North bound train to 002
This is a old PR I think from 2008 before the IP was acquired by British Biotech Corp in 2009.
Chemokine Therapeutics Announces outcomes From CTCE-0214 medical Trials system
January 19th, 2011 | by admin |
http://healthvv.com/2011/01/19/chemokine-therapeutics-announces-outcomes-from-ctce-0214-medical-trials-system/
Chemokine Therapeutics
Corp. (the “40?) (TSX:CTI, OTCBB:CHKT), a biotechnology firm
developing chemokine-based therapies to deal with cancer, blood issues, and
vascular conditions, is happy to announce outcomes of medical trials of its
hematological drug candidate, CTCE-0214.
The firm has accomplished the initially two levels with the 3 element phase
Ib medical trials for CTCE-0214. A complete of 57 regular nutritious volunteers
were evaluated by using numerous doses and evaluating intravenous versus
subcutaneous routes of administration. The research demonstrated CTCE-0214 to
be protected and nicely tolerated when administered intravenously as being a single or
after several doses had been administered on the day-to-day foundation for 5
consecutive days. There had been no really serious adverse occasions noted. topics
receiving subcutaneous administrations of CTCE-0214 did even so encounter
transient injection internet site reactions and nearby ache soon after single and repeated
administration with the drug. As demonstrated in an previously research,
administration of CTCE-0214 subcutaneously resulted within a 300% enhance in
neutrophil counts that peaked at around 12 hrs and had been sustained
above the baseline worth for around 48 hrs soon after every
administration. Administration by using the intravenous route demonstrated a
modest pharmacological neutrophil response to every dose administered soon after
each consecutive day of administration that has a obvious enhance in stem
cell numbers at three days by using colony forming assay strategies.
“209 encouraged by the outcomes of those medical research that will
serve as being a basis for long run improvement of CTCE-0214?, mentioned Dr. Hassan
Salari, President and CEO of Chemokine Therapeutics. “The 3rd element with the
phase Ib trial must supply us with further facts around the
benefits of combining CTCE-0214 with G-CSF.”
The major goal with the lately accomplished phase Ib research
conducted underneath a US-IND was to assess the security of CTCE-0214 in regular
health volunteers also as to assess the results of intravenous versus
subcutaneous administration. The unique protocol was amended to consist of a
subcutaneous cohort of topics for comparison on the planned intravenous
route of administration. These trials are made to check principally the
safety and optimum route of administration of CTCE-0214 in planning for
future medical trials that may assess the mobilization and regeneration
of infection-fighting white blood cells as well as other cells of hematopoietic
(blood) origin within a individual setting.
CTCE-0214 has the possible to revive a cancer individual’s immune process
and blood cells involving cycles of chemotherapy. within this medical situation,
patients may well be capable to acquire aggressive chemotherapy devoid of delay by
restoring infection-fighting white blood cells and rising platelet
counts to defend individuals from bleeding, and/or enhance in blood stem
cells appropriate for transplant.
About CTCE-0214
CTCE-0214 is often a steady peptide agonist of stromal cell-derived factor-1
(SDF-1), a important signaling molecule while in the proliferation, homing, engraftment
and growth of hematopoietic stem cells and white blood cells. SDF-1 is
also thought to get the job done as being a visitors controller for infection-fighting white
blood cells and progenitor cell migration supplying an important operate
to fight immunosuppression. CTCE-0214, primarily based on Chemokine’s preclinical
research, mimics the exercise with the healthy chemokine SDF-1 by rising
the stage of white blood cells (neutrophils), bleeding prevention cells
(platelets) and stem cells (primitive blood forming cells) while in the blood.
These findings happen to be confirmed by way of impartial laboratories at
Memorial Sloan Kettering Cancer middle and Cornell health-related college in New
York along with the Walther Cancer Institute in Indianapolis.
About Chemokine Therapeutics Corp. (TSX: CTI, OTCBB: CHKT)
Chemokine Therapeutics is often a product-focused biotechnology firm
developing prescription drugs while in the discipline of chemokines. Chemokines really are a class of
signaling proteins which play a vital part while in the development,
differentiation, and maturation of cells essential for fighting infection
as nicely as tissue restore and regeneration. Chemokines also have an
important part in cancer metastasis and development. Chemokine Therapeutics is often a
leader in analysis while in the discipline of chemokines and has many items in
various levels of improvement.
Safe Harbor assertion underneath the U. S. personal Securities Litigation
Reform Act of 1995: Statements within this document about managements’
future expectations, beliefs, targets, options or prospects constitute
forward-looking statements that entail dangers and uncertainties, which may possibly
cause real outcomes to differ materially through the statements created. For
this goal, any statements which have been contained herein that will not be
statements of historical reality may possibly be deemed to become forward-looking
statements. devoid of limiting the foregoing, the words “believes”,
“anticipates”, “132?, “intends”, “will”, “170?, “expects”, “144?,
and comparable expressions are meant to recognize forward-looking
statements. you’re cautioned that these kinds of statements are topic to a
multitude of dangers and uncertainties that may induce real outcomes,
future situations, or occasions to differ materially from individuals projected
in the forward-looking statements. These dangers consist of, but will not be constrained
to, individuals linked with all the accomplishment of analysis and improvement applications,
the regulatory approval method, competitors, securing and preserving
corporate alliances, market place acceptance with the firm’s items, the
availability of federal government and insurance coverage reimbursements for that firm’s
products, the power of intellectual house, financing ability, the
potential dilutive results of any financing, reliance on subcontractors and
key personnel as well as other dangers thorough from time-to-time while in the firm’s
public disclosure paperwork as well as other filings with all the U.S. Securities and
Exchange Commission and Canadian securities regulatory authorities.
Forward-looking statements are created as with the date hereof, along with the firm
disclaims any intention and has no obligation or duty, besides as
required by legislation, to update or revise any forward-looking statements,
whether as being a outcome of new facts, long run occasions, or otherwise.
Chemokine Therapeutics Corp
http://www.chemokine.net/
Post a Comment
Name (required)
E-mail (will not be published) (required)
Website
Tags
Alcohol Alzheimer and As at Be blood Brain breast by Can cancer Care Cells Children Clinical Disease Drug FDA for From Health Heart Help in Is May more new of on Patients Phase Research Researchers risk study That the to Treatment UK Use With women
Categories
Abortion
Acid Reflux / GERD
ADHD
Aid / Disasters
Alcohol / Addiction / Illegal Drugs
Allergy
Alzheimer's / Dementia
Anxiety / Stress
Arthritis / Rheumatology
Asbestos / Mesothelioma
Autism News
Back Pain
Bio-terrorism / Terrorism
Biology / Biochemistry
Bipolar
Bird Flu / Avian Flu
Blood / Hematology
Body Aches
Bones / Orthopedics
Breast Cancer
Cancer / Oncology
Cardiovascular / Cardiology
Caregivers / Homecare
Medical Health News
Sponsored Links
Tag cloud
blood Alzheimer Help Research Use Children Health in With That of Heart Researchers the on Can risk Disease Care Be by Is at May for Cells Patients more women new breast Brain Alcohol FDA cancer From Phase and study Treatment to As Clinical Drug UK
Recent Posts
DA feedback On circumstance Kansas AG Kline Cited For Necessity Of Investigations Into Late-Term Abortions, little one intercourse Crimes
Kaiser every day females’s well being coverage Report Highlights challenges connected To 2006 Election
Kaiser day by day girls’s wellness coverage Report Highlights troubles connected To 2006 Elections
NARAL Pro-Choice America Files short In situation demanding New Hampshire Parental Notification Law
Wyo. Gubernatorial Candidate Hunkins Will look for Abortion Ban If Roe Overturned, Mandate 25-Year Sentences For Assaults On Pregnant lady
Archives
March 2011
February 2011
January 2011
December 2010
January 1970
Blogroll
Documentation
Plugins
Suggest Ideas
Support Forum
Themes
WordPress Blog
WordPress Planet
Institutional Buying:
Name Ownership Trend
Previous 8 Qtrs Shares Change % Total
Shares Held % Total
Assets Date
Garrison Bradford & Associates Inc Premium 30,000 0 0 0 12/31/2010
Total: Top 1 Top Institutions Premium 30,000 0 0
CHKT CEO, Mr Walter Korz is also on the board of directors for Wex Pharmaceuticals and the major shareholder there is Pharmagesic:
Pharmagesic Announces Take Up of Additional Shares of WEX Pharmaceuticals Inc.
02/28/2011
Montreal, Canada (February 28, 2011) – Pharmagesic (Holdings) Inc. (“Pharmagesic”) announced today that pursuant to the offer by its wholly-owned subsidiary, 7735308 Canada Limited (the “Offeror” and, together with Pharmagesic, the “Offering Parties”) to acquire all of the outstanding restricted voting shares (the “WEX Shares”) of WEX Pharmaceuticals Inc. (“WEX”) not already owned by Pharmagesic for C$0.14 cash per WEX Share (the “Offer”) it has taken up an additional 54,590 WEX Shares, which, when added to the WEX Shares previously held, amount to a total of 398,496,186 WEX Shares, representing over 90% of the WEX Shares outstanding. It is the current intention of the Offering Parties to enter into a subsequent acquisition transaction to acquire all of the remaining WEX Shares that are not acquired pursuant to the Offer, which is open until 5:00 p.m. (Vancouver time) on March 10, 2011.
WEX shareholders who have already deposited their WEX Shares to the Offer do not need to take any further action to accept the Offer. Shareholders who have not yet deposited their WEX Shares in acceptance of the Offer may tender their WEX Shares to the Offer at any time prior to 5:00 p.m. (Vancouver time) on March 10, 2011.
About WEX Pharmaceuticals Inc.
WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. WEX’s principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market.
About Pharmagesic (Holdings) Inc.
Pharmagesic (Holdings) Inc. is an indirect wholly owned subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”). CKLS is a company listed on The Stock Exchange of Hong Kong Limited (stock code: 0775). Bearing the mission of improving the quality of life, CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing and selling of environmental and human health products, and water business as well as investment in various financial and investment products. Products developed by CKLS are categorized into the areas of human health and environmental sustainability. CKLS is a member of the Cheung Kong Group. For additional information, please visit www.ck-lifesciences.com.
British Canadian BioSciences Corp. Acquires Chemokine Therapeutics
Corp. Technology
http://www.bcbcorp.net/BCBC_PR_Technology_Aquisition_(11Jan10)[1].pdf
But from the looks of things BCBP acquired the whole company.
British Canadian Bioscience corp (a private BC biotechnology company) and CHKT has the same CEO and Science directors, Mr Korz and Mr Wong and also the same IP of CHKT is on the BSBP website, the 28 issued and 9 pending patents for:
1. Therapeutics for chemokine mediated diseases
2. CXCR4 antagonist treatment of hematopoeitic cells
3. Bicyclic aromatic chemokine receptor ligands
4. Therapeutic chemokine receptor antagonists
5. Cyclic peptides for modulating growth of neovessels and their use in therapeutics angiogenesis
6. Novel chemokine mimetics synthesis and their use
7. DNA encoding for recombinant polypeptide mutants of human SDF-1
Link to
http://www.bcbcorp.net/IntellectualProperty.html
Product Pipeline;
1.CTCE-9908 (Anti-Metastasis and Anti-Cancer)
2. CTCE-0214 (Hematological Support; mobilization of stem cells and neutrophils into the circulation)
3.CTCE-0324 (Peripheral Vascular Disease)
I think this is whats up:
VANCOUVER, Jan. 9 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp.
(the "Company") (TSX:CTI, OTCBB:CHKT), a biotechnology company developing
chemokine-based therapies to treat cancer, blood disorders, and vascular
diseases, is pleased to announce that Chemokine Therapeutics (B.C.) Corp.
("CTBCC"), a wholly-owned subsidiary of Chemokine Therapeutics Corp. and
Globe Laboratories Inc. ("Globe"), have entered into a definitive agreement
wherein Globe agreed to sell certain assets (consisting mainly of
laboratory equipment and leasehold improvements) to CTBCC for consideration
of CD$375,935 based on the fair market value of these assets as determined
by an independent appraisal, and to cease all future research and
development services by Globe to the Company.
The acquisition of the assets and the termination of the development
agreement with Globe were initiated by the Company because management
believes that it is in the best interests of the Company to concentrate its
research and development in-house through its wholly-owned subsidiary,
CTBCC.
The Company, under a development agreement dated January 1, 2003 had
engaged Globe to carry out the Company's chemokine-based research work on a
contracted operating cost basis plus a 2% margin. Globe is controlled by
Dr. Hassan Salari and his family. Dr. Salari is also the Company's
President and Chief Executive Officer. Pursuant to this development
agreement between the Company and Globe, all proprietary interest,
including all patent rights, trademarks, copyright, trade secrets, and
confidential information of the research conducted by Globe on our products
is the exclusive property of the Company.
The Company did not incur any early termination obligations by
terminating its research. CTBCC and Globe also entered into a definitive
agreement which provided for Globe's assignment of a partial sublease in
respect of approximately 5400 square feet of laboratory space located at
the University of British Columbia to CTBCC.
In accordance with the terms of the agreement between the Company,
CTBCC and Globe, CTBCC has hired the majority of the former employees of
Globe.
"The purchase of Globe Laboratories Inc. assets and acquisition of key
staff will allow us to have direct control and management of the Company's
R & D activities", said Mr. Walter Korz, V.P., Drug Development at
Chemokine Therapeutics. "This will also help the Company to build on its
core competencies."
About Chemokine Therapeutics Corp. (TSX: CTI, OTCBB: CHKT)
Chemokine Therapeutics is a product-focused biotechnology company
developing drugs in the field of chemokines. Chemokines are a class of
signaling proteins which play a critical role in the growth,
differentiation, and maturation of cells necessary for fighting infection
as well as tissue repair and regeneration. Chemokines also have an
important role in cancer metastasis and growth. Chemokine Therapeutics is a
leader in research in the field of chemokines and has several products in
various stages of development.
Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995: Statements in this document regarding managements'
future expectations, beliefs, goals, plans or prospects constitute
forward-looking statements that involve risks and uncertainties, which may
cause actual results to differ materially from the statements made. For
this purpose, any statements that are contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects", "projects",
and similar expressions are intended to identify forward-looking
statements. You are cautioned that such statements are subject to a
multitude of risks and uncertainties that could cause actual results,
future circumstances, or events to differ materially from those projected
in the forward-looking statements. These risks include, but are not limited
to, those associated with the success of research and development programs,
the regulatory approval process, competition, securing and maintaining
corporate alliances, market acceptance of the Company's products, the
availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, financing capability, the
potential dilutive effects of any financing, reliance on subcontractors and
key personnel and other risks detailed from time-to-time in the Company's
public disclosure documents and other filings with the U.S. Securities and
Exchange Commission and Canadian securities regulatory authorities.
Forward-looking statements are made as of the date hereof, and the Company
disclaims any intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking statements,
whether as a result of new information, future events, or otherwise.
CONTACT: Chemokine Therapeutics Corp., Mr. Don Evans, Director of
Public Relations, Phone: (604) 822-0305 or 1-888-822-0305, Fax: (604)
822-0302, E-mail: devans@chemokine.net, Internet: www.chemokine.net
SOURCE Chemokine Therapeutics Corp.
Yep. Big Volume = Big News coming+super thin L2 = ROCKET LAUNCH
WSRA>News just out on N43101. Up 42%. 20Million in mining properties alone. PPS way under valued.
CHKT>On the move>Up 125%. Super thin L2. 0.0039 up.
CHKT>up 125% again today on volume search. Low float and she moves easy. Huge NEws is coming and soon. PPS @ 0.0036
HUGE earnings just out!
CHGY>HUGE FINS JUST OUT>288% increase in net income. EPS increase from 0.11 in 2009 to 0.39 in 2010. Easy multibagger. Trading @ 1.39 s/be trading in the $4 range based on todays FINS released
CHGY>HUGE FINS JUST OUT>288% increase in net income. EPS increase from 0.11 in 2009 to 0.39 in 2010. That is a 333% increase. Trading @ 1.38 pps. New PPS @ 12.5 times earnings should be 4.87. Easy multibagger
CHGY>HUGE FINS JUST OUT>China Energy Corp. Reports Record Fiscal Year 2010 Results; Revenues increase 103% to $88 million and net income increases 245%. EPS increase from 2009 @ 0.11 to 2010 @ 0.39 fully diluted.
Tue, Mar 01, 2011 12:00 - MOP Environmental Solutions, Inc. (MOPN: OTC Link) - Tier Change - The symbol, MOPN, no longer is classified as OTC Pink Limited. As of Tue, Mar 01, 2011, MOPN resides in the OTC Pink Current tier. You may find a complete list of tier changes at otcmarkets.com.
Reverse Split of 1/20: Reverse stock split. Prior to Closing, China Stationery shall effectuate a 1 for 20 reverse stock split on its issued and outstanding common shares. As a result, at the time of the Merger, there shall only be four hundred nine thousand, five hundred twenty four (409,524) common shares issued and outstanding in China Stationery. Closing of RM expected on or before 3/20.
AS to remain the same at 100Mil as per pre-merger.
Global Arena 2008, 2009 and 2010 FINS to be filed before 3/20.
Our new and VERY IMPRESSIVE BOARD:
CEO:
John Matthews. John Matthews has been the chief executive officer of Global Arena since February 2008. From January 2006 to February 2008, Mr. Matthews was the president of Clark Dodge, a FINRA registered broker/dealer. From January 2003 to September 2005, Mr. Matthews was the chairman of JSM Capital Holding Corp., held the independent contractor agreement for two Office of Supervisory Jurisdictions with vFinance Investments, Inc. and was responsible for all supervision of 35 registered representatives.
Concurrently, during the period from January 2003 until October 2004, Mr. Matthews served as the president of vFinance Investments and was responsible for all retail sales of 165 registered representatives and 28 branch offices.
From 2001 through 2003, Mr. Matthews served as Chairman of Ehrenkranz, King & Nussbaum, a NASD broker/dealer.
From 1996 to 2000, Mr. Matthews served as chairman and chief executive officer of Weatherly Securities Corp., a full service NASD brokerage firm. In May 2000, Weatherly Securities was sold
--------------------------------------------------------------------------------
to Weatherly International PLC, a publicly-traded company listed on the London Stock Exchange's Alternative Investment Market.From 1992 to 1996, Mr. Matthews worked as a registered representative, qualifying as a NASD Series 24 principal in 1992. Over the course of his career, Mr. Matthews has gained extensive experience with the daily operation and administration of a financial services firm.
Prior to entering the securities industry, Mr. Matthews served as the director of former U.S. Senator Daniel Patrick Moynihan's New York office, where he served as the senator's ombudsman responsible for legislative initiatives and constituent services. Mr. Matthews was also actively involved in Senator Moynihan's successful 1988 election campaign.
Mr. Matthews graduated with a bachelor of arts from Long Island University in 1986.
Chairman and CFO:
Josh Winkler. Josh Winkler has been the chairman of the board of Global Arena since February 2008. Mr. Winkler has extensive background and experience in accounting, operations and financing especially in the healthcare, telecommunications, technology, entertainment, finance, among other sectors. In the last several years, Mr. Winkler has been involved in venture and growth capital financing business representing ultra high net worth individuals. He brings with him an extensive managerial and operation experience. From 2006 to 2008, after his retirement from IDT and Net2Phone, Mr. Winkler worked at BullDog Entertainment, LLC in the entertainment sector in ticketing and promotions, a company which was later sold to Warner Music Group.
From 1995 to 2002, Mr. Winkler served as the president of the retail division of IDT Corporation (NYSE: IDT), where he was an executive officer and member of the board of directors. His executive duties put him in control of the worldwide phone cards division. He also spun off a group known as Net2Phone which was later sold to AT&T. Prior to 1995, Mr. Winkler was the president of a leading medical complex and laboratory that provided family primary and urgent care for over ten years until it was sold. Prior to 1985, Mr. Winkler practiced as a certified public accountant for nearly ten years for national accounting and audit firms including Oppenheimer, Apple, Dixon & Company and other firms with strong taxation practices.
The new directors:
Michael Cohn - (runs Global Investment Management LLC) has been a financial services professional for over 22 years. Since 2004, Mr. Cohn was the portfolio manager and chief investment strategist at Atlantis Asset Management. His specialties are equities, derivatives, commodities and fixed income strategies using innovative risk management techniques to preserve wealth, and create high income and growth oriented portfolios with lowered market risk.
From 1995 to 2003, he was the President and Managing Partner of Raymar Capital Inc., a stock and option specialist firm on the American Stock Exchange. Mr. Cohn started his career in 1985 at Bear Stearns & Co. in New York City. His experience there included Treasury bond trading, mortgage backed securities trading and underwriting, risk arbitrage, and OTC trading. He has been a member of both the New York and American Stock Exchanges. Mr. Cohn is a risk management consultant to other asset managers and financial advisors on using derivatives to manage risk and create income. Mr. Cohn has been quoted on CNBC and in major financial print publications such as Forbes, Wealth Manager, Financial Planning and others. Mr. Cohn has had articles published in journals such as the Journal of Wealth Management.
John Piazza,GACC and GATT is directed by its President who brings over 20 years of financial trading experience.
Mr. Piazza is licensed with the NFA and has been a member of the American Stock Exchange and the New York Mercantile Exchange. From 2006 to 2007, he worked with the Commodities Division of Clark Dodge & Company.
From 2003-2006, he was an independent trader and broker on the trading floor of the COMEX Division of the NYMEX, trading and managing a portfolio of gold and silver futures and options in addition to executing customer orders. From 1986 to 2003, Mr. Piazza joined Triple J Trading, LLP, a successor to S&S Securities, as a manager of the group, responsible for developing and implementing strategies to manage risk.
Mr. Piazza was a independent option principal member of the AMEX, acting as a market maker in listed equity and index options and trading these securities as well as equities and derivative products in a proprietary account. Mr. Piazza began his career in 1981 on the trading floor of the American Stock Exchange with the firm of Dritz, Goldring, and Wohlreich. As a specialist in corporate bonds, equities, and equity and index options, Mr. Piazza was responsible for trading in the firm account while serving as the primary market maker in these securities. Mr. Piazza became a registered member of the National Future Association and a licensed Member of the New York Mercantile Exchange. Mr. Piazza attended Yale University and holds Series 3 and Series 7 commodity and securities industry licenses.
The Company maintains one office, located at 708 Third Avenue, 11th Floor. New York, New York, 10017
LE -Ms. Kathryn Weisbeck is the Chief Executive Officer of LE and is the sole owner of the remaining 33%. Ms. Weisbeck is a member of the Screen Actors Guild, American Federation of Television and Radio Artists, Actors Equity, and Film Independent; host of the Independent Spirit Awards.
In 2003 Kathryn graduated With Honors from Loyola Marymount University earning a Bachelor of Arts in Dance and a second degree, Bachelor of Arts in Individualized Study: Musical Theatre. The program she created is now offered as a BA in Musical Theatre by the school. During her time at LMU, Kathryn participated in many student films, theatre productions and dance concerts, was a projectionist for film classes, was a member of Sursum Corda, a service organization, directed and choreographed Jesus Christ Superstar, and toured the US with their highly regarded Concert Choir.
Ms. Weisbeck has appeared on As the World Turns, ER, Canterbury's Law and worked on films; 27 Dresses, (500) Days of Summer, The Accidental Husband, Solitary Man as well as numerous independent films and countless plays including West Side Story, Singin' in the Rain, Anything Goes, Macbeth, and Oliver.
The New Company, Global Arena Holding Subsidiary Corp., a Delaware corporation, is a holding company and owns operates through its subsidiaries, Global Arena Investment Management LLC, Global Arena Commodities Corp., Global Arena Trading Advisors LLC,Lillybell Entertainment LLC and a minority owned investment in Global Arena Capital Corp.
The websites for each of the subsidiaries:
Global Arena Investment Management LLC (Registered Investment Advisor with the Securities Exchange Commission, Central Registry Deposit (CRD) Number 135835. GAIM currently manage approximately $110,000,000 in separately managed accounts, the majority of which are held at held Fidelity Advisor.
http://www.globalarenaim.com/
Global Arena Commodities Corp (NFA Registered Commodities Firm)
http://www.globalarenaim.com/Commodities/index.html
Global Arena Capital Corp. Global Arena Holding owns 4.8% of Global Arena Capital and Global Arena Capital currently manages approximately $220,000,000 and clears its securities business, on a fully disclosed basis, thru RBC Correspondent Services, a division of RBC Capital Markets, a member of the New York Stock Exchange Euronext, FINRA and SIPC
http://www.globalarenacapital.com/GlobalArena/index.html
Global Arena Trading Advisors LLC and LillyBell Entertainment LLC has no website as of today.
The New Company, Global Arena Holding Subsidiary Corp., a Delaware corporation, is a holding company and owns operates through its subsidiaries, Global Arena Investment Management LLC, Global Arena Commodities Corp., Global Arena Trading Advisors LLC,Lillybell Entertainment LLC and a minority owned investment in Global Arena Capital Corp.
The websites for each of the subsidiaries:
Global Arena Investment Management LLC (Registered Investment Advisor with the Securities Exchange Commission, Central Registry Deposit (CRD) Number 135835. GAIM currently manage approximately $110,000,000 in separately managed accounts, the majority of which are held at held Fidelity Advisor.
http://www.globalarenaim.com/
Global Arena Commodities Corp (NFA Registered Commodities Firm)
http://www.globalarenaim.com/Commodities/index.html
Global Arena Capital Corp. Global Arena Holding owns 4.8% of Global Arena Capital and Global Arena Capital currently manages approximately $220,000,000 and clears its securities business, on a fully disclosed basis, thru RBC Correspondent Services, a division of RBC Capital Markets, a member of the New York Stock Exchange Euronext, FINRA and SIPC
http://www.globalarenacapital.com/GlobalArena/index.html
Global Arena Trading Advisors LLC and LillyBell Entertainment LLC has no website as of today.
MM battles to keep them 55's. Hope for firework EOD
EVCA going to rock next week. In @ 0.032 today....
Tomorrow is going to be BIG with all the eyes on it! With that expect the slime to come out of their holes trying to keep the MoMo down but they are going to get burned! The float is all but locked!
Float traded and locked. Multi day multibagger here. Looking for a close tomorrow of 05+
Wow.Float almost traded!
02 breakout then we are really going to go to 03. MM's almost out of shares.
About to touch first resistance point. Holding my breath here
This is a pressure cooker now. Once float is traded watch out!
Traded almost more than 60% of the float so far today. Float is 78,473,156 as of Nov 2010 and looks too be still accurate.
Resistance points is 0.0167 and 0.022. If we can break and run past that then it's blue sky break out. The MM's wants to move this north so a steady climb is preferred. That way we build nice support levels along the way.